Compare Cronos Group Inc (CRON) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Nomura Holdings Inc — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while Nomura Holdings Inc trades at $9.57 (market cap $27.55B). The key difference: Nomura Holdings Inc is far larger — about 23.3× Cronos Group Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Nomura Holdings Inc for 55 Days on average.
| CRON | NMR | |
|---|---|---|
Market Cap | $1.18B | $27.55B |
Volume | 968,037 | 782,470 |
Sector | Health | Financials |
52-Week High | $3.55 | $10.86 |
52-Week Low | $2.30 | $6.73 |
Typical Hold Time | 22 Days | 55 Days |
Enterprise Value | $387.62M | $38.54T |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $146.59M in 2025, but net income was -$9.45M. Recent Q2 2026 earnings beat expectations with EPS of $0.09. The company held its first Investor Day in September 2026, highlighting international expansion and cash flow focus.
Outlook is mixed: strong revenue growth and a solid balance sheet with no debt support upside, but profitability remains inconsistent. Risks include cash flow volatility and competitive pressures. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty amid expansion efforts.
Nomura Holdings (NMR) trades at $9.53, down 2.56% today amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $1.66T in 2025 and net income margin of 20.4%, but recent earnings misses and negative operating cash flow raise concerns. Valuation appears reasonable with P/E of 11.33 and P/B of 1.15. Analyst sentiment is cautious with 67% hold ratings despite recent Zacks strong buy recommendations.
The outlook remains balanced - attractive valuation and revenue growth potential are offset by cash flow challenges and technical weakness. Key risks include Japan's fiscal policy impacts on bond markets and sustained negative operating cash flow. Investors should weigh the discounted valuation against execution risks in the current macroeconomic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
